New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
11:06 EDTPLDLF, ENDPEndo completes acquisition of Paladin Labs
Endo International (ENDP) announced that it has completed the acquisition of Paladin Labs (PLDLF) in a stock and cash transaction currently valued at approximately $2.7B. The acquisition accelerates Endo's strategic transformation into a leading global specialty healthcare company and creates a platform for future growth in North America and around the globe. In connection with the acquisition, Endo and Paladin Labs have been combined under a new company incorporated in Ireland named Endo International. Shares of Endo International will trade on NASDAQ under the ticker symbol ENDP and the Toronto Stock Exchange under the ticker symbol ENL. Under the terms of the transaction, Paladin Labs shareholders received 1.6331 shares of Endo International stock and C$1.16 in cash for each Paladin Labs share they owned upon closing. In addition, for each Paladin Labs share owned at closing, shareholders of Paladin Labs received one share of Knight Therapeutics a newly formed Canadian company that has been separated as part of the transaction. Shareholders of Endo Health Solutions received one share of Endo International for each share of Endo Health Solutions they owned upon closing.
News For ENDP;PLDLF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:57 EDTENDPPerrigo confirms first to file patent challenge for generic version of Aveed
Subscribe for More Information
07:11 EDTENDPTrimel announces license agreement with Endo for NATESTO
Subscribe for More Information
07:02 EDTENDPEndo acquires rights to Natesto testosterone nasal gel
Endo announced the acquisition of rights to Natesto, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporatio. Natesto™ was approved by the FDA in May of 2014. Under the terms of the agreement Trimel will receive an upfront payment of $25M and could receive additional payments upon the achievement of certain regulatory and sales milestones. Additionally, Trimel will be responsible for the manufacture and supply of Natesto and Endo will pay a tiered supply price for the product. Endo expects the transaction to close in early 2015. Under the terms of the agreement, Endo receives sole and exclusive commercial rights to the Natesto product in the US and Mexico. In addition, Endo will collaborate on all regulatory and clinical development activities in coordination with Trimel.
November 20, 2014
07:33 EDTENDPEndo launches generic version of Hoffmann-La Roche's Valcyte
Endo's Qualitest subsidiary has launched a generic version of Hoffmann-La Roche's Valcyte. For the 12 months ending September 30, Valcyte had total U.S. sales of approximately $440M, according to IMS Health data.
November 19, 2014
10:21 EDTENDPHigh option volume stocks
Subscribe for More Information
07:33 EDTENDPEndo, Auxilium receive early termination of HSR waiting period for deal
Subscribe for More Information
November 14, 2014
09:38 EDTENDPJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use